Table 1. Effects of Hypoxia and Subsequent CK-2019165 or Nitroprusside.

	Pre-Hypertension Baseline	Pulmonary Hypertension baseline	Hypoxia Model (CK-165) % change		Hypoxia Model (Nitroprusside) % change
	(n = 6)	(n = 6)	Intravenous (n = 5)	Inhalation (n = 6)	Intravenous (n = 6)	Inhalation (n = 6)
Heart Rate (bpm)	125±7.7	146±9.4	8.7±1.0%‡	3.3±0.8%‡ ##	8.6±2.7%†	−0.4±0.8%
Mean Arterial Pressure (mmHg)	97±3.1	71±1.8**	−10.7±2.8%† ##	−0.6±1.0%	−25.9±2.5%‡	2.5±3.4%
Mean Pulmonary Artery Pressure (mmHg)	17.8±0.3	28.8±1.0**	−13.7±2.4%‡	−13.9±3.3%‡	−22.6±3.4%‡	−12.2±1.4%‡
Pulmonary Blood Flow (L/min)	2.6±0.1 (n = 5)	2.8±0.2 (n = 5)	9.4±1.1%‡ ##	1.5±1.3% (n = 5)	4.2±2.2% (n = 5)	1.5±1.0% (n = 5)
Pulmonary vascular resistance (mmHg/L/min)	4.0±0.3 (n = 5)	8.1±1.0** (n = 5)	−21.9±2.9%‡	−17.2±5.7%† (n = 5)	−14.7±4.7%† (n = 5)	−13.2±3.1%† (n = 5)

^*p<0.05 Pulmonary Hypertension vs. Pre-Hypertension Baseline.

^**p<0.01 Pulmonary Hypertension vs. Pre-Hypertension Baseline.

^†p<0.05 Hypertension Baseline vs. Subsequent CK-2019165 or nitroprusside.

^‡p<0.01 Hypertension Baseline vs. Subsequent CK-2019165 or nitroprusside.

^#p<0.05 CK-2019165 vs. nitroprusside.

^##p<0.01 CK-2019165 vs. nitroprusside.